Today, I'll provide an update on the Rezdiffra launch, where we ended our first full year on the market at nearly $1 billion in net sales and solidified Rezdiffra as the foundational therapy in MASH.

Q4 2025 Earnings Call February 26, 2026 10:00 PM ESTCompany ParticipantsEdwin NgMegat Bin Megat Hassan - President, CEO ...

Good afternoon, everyone, and welcome to Solvay's Fourth Quarter and Full Year 2025 Earnings Call. I'm Geoffroy d'Oultremont, Head of Investor Relations. And with me today are our CEO, Philippe Kehren ...